Eli Lilly’s chief technology officer retires after 35 years; Astellas strategy exec resignsnews2026-04-02T11:00:47+00:00April 2nd, 2026|Endpoints News|
Immunovant’s FcRn drug fails in a pair of Phase 3 trials in thyroid eye diseasenews2026-04-02T09:54:01+00:00April 2nd, 2026|Endpoints News|
Gilead ends a Phase 2/3 trial of long-acting HIV pillsnews2026-04-01T23:18:50+00:00April 1st, 2026|Endpoints News|
Noom plans push into peptides beyond weight loss drugsnews2026-04-01T20:47:39+00:00April 1st, 2026|Endpoints News|
Making custom CRISPR therapies could be harder than initially thoughtnews2026-04-01T19:40:47+00:00April 1st, 2026|Endpoints News|
To counter China, FDA chief wants to speed new drug trial processnews2026-04-01T19:15:42+00:00April 1st, 2026|Endpoints News|
Novo cuts 400 jobs in Indiana as Scholar Rock refiles drug linked to the factorynews2026-04-01T16:39:35+00:00April 1st, 2026|Endpoints News|
Eli Lilly wins approval of anti-obesity pill orforglipronnews2026-04-01T15:41:36+00:00April 1st, 2026|Endpoints News|
Amgen, Zai Lab team up on DLL3; Janux gets $35M milestone paymentnews2026-04-01T15:26:47+00:00April 1st, 2026|Endpoints News|
Paragon offshoot Korsana to go public in reverse merger for Alzheimer’s worknews2026-04-01T15:20:48+00:00April 1st, 2026|Endpoints News|
